Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs Etigilimab (Primary) ; Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors OncoMed Pharmaceuticals
  • Most Recent Events

    • 06 Dec 2018 Status changed from recruiting to active, no longer recruiting.
    • 09 Nov 2018 Results presented in the OncoMed Pharmaceuticals media release.
    • 09 Nov 2018 According to an OncoMed Pharmaceuticals media release, results from this trial were presented today at the Society for Immunotherapy of Cancer meeting taking place in Washington, D.C.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top